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1. Introduction
The South African Allergic Rhinitis Working Group 
(SAARWG) met on 6 April 2013 to discuss and review 
important concepts in allergic rhinitis diagnosis and 
management. The theme of that meeting, and this 
update, is to remind clinicians that all patients with rhinitis may 
not have allergic rhinitis (AR) specifically. The reason is twofold: 
(i) patients with chronic rhinitis (CR) may have one of a number of 
conditions that are more significant and may herald more sinister 
diagnoses, and (ii) many forms of chronic rhinitis may not respond 
as well to standard allergic rhinitis therapy. This review will focus 
specifically on the differential diagnosis of AR and the management of 
these alternative conditions.
2. Definitions
The term ‘rhinitis’ implies inflammation of the lining of the nose. The 
characteristic symptoms are a blocked nose, anterior and posterior 
rhinorrhea, sneezing and itching.[1] Most patients with AR have an IgE 
or type I allergic basis,[2] and the Allergic Rhinitis and its Impact on 
Asthma (ARIA) Working Group has classified allergic rhinitis into 4 
groups based on symptom duration and symptom severity (Fig. 1).[3] 
This classification has become important for South Africa, because 
where grass pollen is a major allergen (such as across the Highveld) the 
disease is usually persistent over several months and usually moderate 
to severe in nature.[4] In contrast, chronic non-allergic rhinitis, by 
definition, is a condition where ongoing rhinitic symptoms are present 
for many months (as for persistent AR)[3] but where there is no IgE 
basis. A long list of conditions may present as CR (Table 1).
3. Prevalence of CR
South Africa was fortunate enough to be represented in the 
International Study of Asthma and Allergies in Childhood (ISAAC). 
Two centres (Cape Town and Polokwane) participated in this study of 
the epidemiology of allergic rhinitis. In Phase I of the ISAAC Study, 
conducted in 1995, questioning of 13 - 14-year-old subjects reported 
that the prevalence of AR was 30.4% in Cape Town.[5] By Phase II of 
the study in 2003, the prevalence had gone up to 38.5%.[6] In addition, 
that study revealed that AR’s impact on quality of life was becoming 
more significant.[6] However, the major problem with these data is 
that although the subjects’ condition was labelled as AR, no testing 
for allergy was performed. This raises a concern about the above 
epidemiological definition of AR and its prevalence. 
It is clear that when subjects are questioned on the presence of nasal 
symptoms, a significantly higher rate of symptoms is reported than for 
true AR. For example, in one study, although 48% of subjects reported 
chronic nasal symptoms, only 14.9% had true AR with a positive skin 
-prick test (SPT).[7] This study emphasises that the term AR should 
not be used unless there is either a positive allergy test (either SPT 
or ImmunoCAP) or a clear history of symptoms triggered by specific 
allergens, possibly with a seasonal variation. If such evidence of allergy 
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is not present, then the condition should be labelled as CR and the 
conditions listed in Table 1 should always be considered. 
Another important consideration in defining AR is that a positive 
allergy test does not always confirm AR in isolation. Specific IgE may 
be a pointer to AR but specific symptoms need to be present before 
the diagnosis is made.[8] Laboratory tests to confirm the diagnosis of 
AR should be selected based on careful history-taking, rather than 
applying a large panel of allergy tests.
In children the allergic component of CR may be more frequent 
than in adults.
4. Climate change, urban air pollution 
and CR
We live in a dynamic environment, with rising average temperature 
and increasing anthropogenic greenhouse gases, which may increase 
the generation of pollen-producing plant species.[9,10] Increased levels 
of pollutants such as carbon dioxide, ozone and nitrogen dioxide 
enhance the allergic response,[11] and pollutants may induce their 
own form of irritant rhinitis. Changes in vegetation biomes, as a 
result of climate change, are likely to cause changes in outdoor pollen 
and fungal allergens. Changes in the climate are expected to alter the 
presentation, seasonality and epidemiology of allergic rhinitis and 
other allergic respiratory diseases in future. 
5. Impact of rhinitis on South Africans
In light of the statement above that most epidemiological studies of 
AR are in fact studies of CR, there are valuable lessons to be learned 
from studies of the impact of rhinitis on quality of life.[12] Many 
South African studies have suggested that CR impacts significantly 
on patient quality of life and the major effect is impaired sleep.[13-15] 
Trivialising CR as a minor, non-life-threatening illness promotes the 
idea that CR does not affect patients significantly. However, CR may 
result in significant co-morbidity, presenteeism and absenteeism from 
work and school.
Table 1. Causes of chronic rhinitis (CR)
•  Allergic rhinitis (intermittent or persistent)
•  Local allergic rhinitis
•  Non-allergic rhinitis:
 •  Acute exacerbation of a low-grade chronic rhinitic condition 
(e.g. By a common cold)
•   Drug-induced: rhinitis medicamentosa caused by topical 
decongestants or other drugs (beta-blockers, ACE inhibitors, 
reserpine, calcium channel blockers, methyldopa, alpha-
receptor antagonists, phosphodiesterase-5 inhibitors, aspirin, 
NSAIDS, oral contraceptives)
•  Vasomotor rhinitis (non-allergic rhinopathy)
•  Occupational rhinitis
•  Chronic infective rhinosinusitis
•  Gustatory rhinitis
•  Pregnancy-associated rhinitis
•  Primary ciliary dyskinesia
•  Primary or secondary immune deficiency
•  Cystic fibrosis
•  Senile rhinitis





One or more items





Normal work and school
No troublesome symptoms
>4 days per week
And >4 weeks
Abnormal sleep
Impairment of daily activities,
sport, leisure




421  June 2013, Vol. 103, No. 6  SAMJ
6. Local allergic rhinitis
Recently, local allergic rhinitis (LAR) has been recognised as 
a condition.[16] In LAR, patients report typical allergy-induced 
rhinitic symptoms but all IgE-based allergy testing is negative. IgE 
is produced locally in response to allergens in the nose, but not 
systemically.[16] Only provocation testing diagnoses the problem; 
however, these tests are not widely available and only a limited 
number of allergens can be tested. However, patients with this 
condition do respond to the usual treatments for AR (including 
antihistamines and intranasal steroids).
7. Treating CR
Antibiotics must not be used for a ‘cold’.[17] Upper respiratory tract 
infections are usually viral, and antibiotic use in this condition only 
leads to the evolution of resistant flora.
Previous SAARWG guidelines have discussed the therapeutic 
modalities for AR in depth.[18,19] Topical use of corticosteroids remains 
the drug of choice, although antihistamines appear to be more 
acceptable for the treatment of young children and are effective. 
Allergen immunotherapy is an important therapeutic option.
Aspirin-induced respiratory disease is a condition where 
sensitivity to non-steroidal anti-inflammatory drugs leads to asthma, 
nasal symptoms and polyposis. Therapy involves specific aspirin 
desensitisation and avoidance of Cox-I inhibitors. Montelukast is a 
useful therapeutic option for some patients.[20]
Therapy of non-allergic, so-called ‘vasomotor’ rhinitis is difficult. 
There is no standard therapy which always works. Some patients 
respond to intranasal corticosteroids,[21] and other therapies that 
may work in selected patients are topical anticholinergics[22] and 
occasional use of topical decongestants. However, the benefit of 
topical decongestants often leads to the overuse of this form of 
therapy, which may lead to rebound or rhinitis medicamentosa.
8. Surgical intervention for CR
A number of anatomical abnormalities of the nose and sinuses may 
cause rhinitis symptoms and many may co-exist with AR. Thus at 
some stage in the medical management and investigation of CR, 
where therapy is ineffective, the patient should be evaluated for 
anatomical abnormalities, including septal deviation, nasal polyposis 
and tumours of the nose and sinuses. Referral to a specialist and 
radiological imaging may be necessary.
Every patient who experiences chronic snoring must be investigated 
for CR and have the condition managed adequately. If the snoring 
Table 2. Recommendations for action in treating chronic 
rhinitis (CR)
•   Consider CR as a multifactorial condition of which AR is only 
one cause
•   Long-term studies of change in prevalence of CR in relation to 
climate change are needed
•   The AR Essential Drug List (EDL) for South Africa should 
be updated to reflect safe and effective therapy – sedating 
antihistamine therapy must not be recommended
•   Medical aid organisations must be encouraged to allow therapy 
for CR to be paid for through chronic benefits
•  Medication should be tailored to individual patients
•  Patient education for CR is very important
Table 3. World Anti-Doping Agency (WADA): Chronic rhinitis (CR) drugs that are permitted and not permitted in sport
Treatment WADA rules Notes
Antihistamines Permitted (WADA 2006) Second-generation antihistamines should be 
preferred, to avoid cardiotoxic effects and 
somnolence. (Nothing mentioned: WADA 2013)
Antileukotrienes Permitted (WADA 2006) Nothing mentioned: WADA 2013
Oral steroids Prohibited All glucocorticoids prohibited
Topical steroids Require an abbreviated therapeutic use 
exemption (WADA 2006)
Nothing mentioned: WADA 2013
Oral beta-2 agonists Prohibited
Inhaled salbutamol, formoterol or 
salmeterol
Require an abbreviated therapeutic use 
exemption
The presence in urine of salbutamol in excess of 
1 000 ng/ml or formoterol in excess of 40 ng/ml 
is presumed not to be an intended therapeutic 
use of the substance. It will be considered an 
adverse analytical finding unless the athlete 
proves, through a controlled pharmacokinetic 
study, that the abnormal result was the 
consequence of the use of the therapeutic inhaled 
dose up to the maximum indicated above
Ephedrine methylephedrine Prohibited Each of ephedrine and methylephedrine is 
prohibited when its concentration in urine is 
greater than 10 µg/ml 
Pseudoephedrine Prohibited Pseudoephedrine is prohibited when its 
concentration in urine is greater than 150 µg/ml
Immunotherapy Permitted Subcutaneous immunotherapy injections should 
not be performed before or after physical exercise
422  June 2013, Vol. 103, No. 6  SAMJ
GUIDELINES
continues, they should be evaluated and managed for adenoidal 
hypertrophy. This is particularly important in children, who are at 
risk of developing right-sided heart failure and cor pulmonale.
9. New international guidelines on 
CR/AR
Doctors in South Africa have regularly updated AR guidelines for 
local application.[1,18,19] The previous revision of the ARIA guideline 
has suggested 10 areas that require global applicability of ARIA and 
have unmet needs.[23] Recent South African guidelines have addressed 
some of these issues. There are, however, some areas, especially for 
CR, that still require attention (Table 2).
10. Sport and CR
Competitive sportsmen may experience significant rhinitic symptoms 
and require that their symptoms be managed.[24] A number of reasons 
for this phenomenon have been proposed.[24] Care must be taken with 
medication because of potential adverse effects and/or ‘anti-doping’ 
codes. Permitted and banned medications are listed in Table 3.[25]
11. Doctor and patient education for 
CR
Patients with CR must be educated about their condition and therapy. 
Clinical studies indicate that only 31% of patients are regularly shown 
how to use nasal sprays.[26] There is good evidence from international 
and local studies that patients are frustrated by CR – education helps 
to allay fears and concerns, and improves medication compliance.[26,27]
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